<u>Drug Injury Watch: November 2012 Litigation And Settlement</u> Update: YAZ, Yasmin, Ocella, And Gianvi Lawsuits

Bayer Has Settled Less Than Half The DVT And PE Blood Clot Claims Filed Or Subject To Apparent Tolling Agreements

(Posted by Tom Lamb at www.DruglnjuryWatch.com on November 26, 2012)

SUMMARY: Based on some information found in the Bayer Stockholders' Newsletter which covered its third quarter financial reporting, it appears that Bayer has quite a ways to go with regard to settling the remaining, and still increasing, number of YAZ, Yasmin, Ocella, and Gianvi claims involving pulmonary embolism (PE) and/or deep vein thrombosis (DVT).

There was not a single mention of Beyaz nor Safyral that I could find in this Bayer Stockholders' Newsletter.

One wonders when we will start to hear from Bayer about the number of Beyaz and Safyral legal claims involving PE and/or DVT blood clot side effects.

[Read this article in full at original source]

Earlier DRSP Birth Control Pills articles by Tom Lamb on the Drug Injury Watch blog:

2012 FDA Report On Beyaz Points Out That Younger Women and Girls Are Most At-Risk For Blood Clots

Bayer Settlements: Gianvi / Ocella / Yasmin / YAZ: July 2012 Update On Drug Injury Lawsuits Filed To Date

Medical Study Finds Link Between YAZ / Yasmin And Irritable Bowel Syndrome (IBS) Coming From Drospirenone (DRSP) Progestin

<u>Bayer Settlements For YAZ / Yasmin Lawsuits Involving Blood Clot Side Effects Like Deep Vein Thrombosis And Pulmonary Embolism</u>

April 2012 Yasmin / YAZ Label Change: FDA Warns About Increased Risk Of Blood Clots Possible Due To Drospirenone

Attorney <u>Tom Lamb</u> represents people in personal injury and wrongful death cases involving unsafe prescription drugs or medication errors. The above article was posted originally on his blog, **Drug Injury Watch** – with live links and readers' Comments.

http://www.DrugInjuryWatch.com